Overview: Celiac Disease Screening Panel
Introduction: The Celiac Disease Screening Panel is a diagnostic tool designed to screen for celiac disease using serum samples. In India, celiac disease prevalence is 0.5-1 percent (higher in northern states due to wheat consumption), with anti-tTG IgA as sensitive marker and total IgA to rule out IgA deficiency. Symptoms include diarrhea, malabsorption, growth failure in children, anemia. High morbidity from underdiagnosis in rural wheat-consuming populations, limited gastroenterology access, delayed gluten-free diet leading to nutritional deficiencies or lymphoma risk. Per gastroenterology practices aligned with ICMR and Indian Society of Gastroenterology guidelines, the test employs immunoassay for anti-tTG IgA and total IgA over 1-2 days with high sensitivity/specificity, valuable for initial screening in symptomatic or at-risk individuals. This diagnostic falls under autoimmune screening and targets patients with GI symptoms or malabsorption, addressing accurate detection to guide biopsy and diet. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing complications. Its serum-based approach ensures reliable detection.
Other Names: Celiac Scr Pnl.
FDA Status: FDA approved, CLIA certified for immunology, compliant with 2025 standards.
Historical Milestone: Anti-tTG standard; in India, prominence with wheat-related celiac rise.
Purpose: The test screens for 2 parameters including anti-tTG IgA to guide celiac disease assessment, detect autoimmunity, inform gluten-free diet.
Test Parameters: 1. Anti-tTG IgA, 2. Total IgA.
Pretest Condition: No fasting required; patients should report diarrhea, weight loss, anemia, or family history.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on GI symptoms, growth issues, anemia, wheat intolerance, family celiac history.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated celiac including malabsorption, benefits of early detection, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis, or IgA deficiency can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Positive anti-tTG IgA indicates celiac disease, necessitating specialist input. Normal may require follow-up if symptoms persist.
Specialist Consultation: Gastroenterologists should be consulted for management.
Additional Supporting Tests: Duodenal biopsy for confirmation.
Test Limitations: False negatives on gluten-free diet; comprehensive approach required.
References: Indian Journal of Gastroenterology 2024, Celiac Disease Studies India 2023.
